Ginkgo biloba and acetazolamide for acute mountain sickness: Exclusion of high risk, low status groups perpetuates discrimination and inequalities

BMJ 2004; 329 doi: https://doi.org/10.1136/bmj.329.7458.171-b (Published 15 July 2004) Cite this as: BMJ 2004;329:171
  1. Jean Adams (j.m.adams@ncl.ac.uk), research fellow
  1. School of Population and Health Sciences, University of Newcastle upon Tyne, Newcastle upon Tyne NE2 4HH

    EDITOR—Gertsch et al report the results of a randomised controlled trial of ginkgo biloba and acetazolamide for acute mountain sickness in trekkers in the Everest region of Nepal.1 However, it is …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription